The Shifting Sands of Commerce: A Week of Bold Plays and Strategic Pivots
The Biotech Dance: Novartis Eyes Avidity in a Blockbuster Bid
Pharma's Big Win: How a Judge's Ruling Ignited Big Pharma Stocks
Novartis Plots Strategic Price Adjustments in US as Trump's MFN Deadline Looms
Unlocking Monopar's Potential: A Speculative Bet on Imminent Cancer Breakthroughs